Skin Disease in Methamphetamine Abuse

Status Not yet recruiting

Clinical Trial Summary

1. To detect the skin diseases in patients using methamphetamine

Clinical Trial Description

Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue. Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body. Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include: - Weight loss - Paranoia - Hallucinations - Aggressive behavior - Being easily distracted - Tooth and gum decay - Changes in brain structure ;

Study Design

Related Conditions & MeSH terms

Methamphetamine Abuse

Clinical Trial Details

NCT number	NCT05971043
Study type	Observational
Source	Assiut University
Contact	asmaa mohamed, master
Phone	+201097507017
Email	amelnakeeb@gmail.com
Status	Not yet recruiting
Phase
Start date	August 3, 2023
Completion date	September 20, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05916989` - Stimulant Use and Methylation in HIV
Recruiting	`NCT04927143` - Encouraging Abstinence Behavior in a Drug Epidemic	Phase 2
Completed	`NCT03226223` - Pharmacogenetics of Naltrexone for Stimulant Abuse	Phase 2
Not yet recruiting	`NCT05593796` - Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder	N/A
Completed	`NCT02907853` - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa	N/A
Recruiting	`NCT04616625` - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Completed	`NCT04061941` - Change in Cognitive Function in Stimulant Users
Completed	`NCT01967381` - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse	Early Phase 1
Terminated	`NCT01019707` - Safety Assessment of Atomoxetine With MA IV Administration	Phase 1
Completed	`NCT01011829` - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	Phase 2
Active, not recruiting	`NCT04706624` - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics	N/A
Recruiting	`NCT05700994` - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)	N/A
Completed	`NCT04109014` - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk	N/A
Completed	`NCT03336866` - Study of Antibody for Methamphetamine Outpatient Therapy	Phase 1/Phase 2
Completed	`NCT01822132` - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade	N/A
Completed	`NCT01062451` - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence	Phase 1
Not yet recruiting	`NCT06233799` - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder	Phase 3
Recruiting	`NCT05521854` - Contingency Management for Drug Use: Does Age Matter?	N/A
Completed	`NCT01063205` - NAC as a Potential Treatment for Methamphetamine Dependence	Phase 1
Not yet recruiting	`NCT05334914` - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals	N/A